Aurobindo Pharma subsidiary CuraTeQ Biologics and U.S. firm BioFactura have terminated their agreement relating to BFI-751, a proposed biosimilar to Janssen Biotech’s Stelara (Ustekinumab).
The decision is aligned with CuraTeQ’s strategic portfolio prioritisation and not expected to have a material impact on the company’s overall biosimilars strategy, Aurobindo Pharma said in a filing on Saturday. Ustekinumab is a recombinant monoclonal antibody used for treating Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
As per their July 7, 2023 agreement, BioFactura was to receive license fees spread across different milestones leading to commercialisation in regulated markets and CuraTeQ the global manufacturing rights. CuraTeQ was to receive 57 – 60% of the profits, from the biosimilar, depending upon the markets. In 2022, Stelara (Ustekinumab) had global sales of around $9.72 billion.
Published – December 27, 2025 07:12 pm IST
